Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcoma

Watanabe, Hideomi; Kanbe, Katsuaki; Chigira, Masahiro

doi:10.1007/bf01753982

Cited by 16 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several molecules involved in cell motility, such as PGI/AMF and RhoA, were reported to increase the permeability of vascular endothelium [23, 27], and therefore we investigated the effect of angiogenic and lymphangiogenic factors and PGI/AMF on the motility of lymphatic endothelial cells. PGI/AMF is a molecule secreted from tumor cells, including fibrosarcoma and osteosarcoma cell lines, and stimulates the motility of tumor cells in an autocrine or paracrine fashion [28, 29]. We expected that this molecule also affects lymphatic endothelial cell motility and affects the stability of endothelium; however, the current study revealed that only VEGF-C and -D, but not PGI/AMF, up-regulated the random motility of lymphatic endothelial cells.…”

Section: Discussionmentioning

confidence: 57%

Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas

Yanagawa

Shinozaki

Watanabe

et al. 2012

Experimental Cell Research

Self Cite

View full text Add to dashboard Cite

Studies on lymph node metastasis of soft tissue sarcomas are insufficient because of its rarity. In this study, we examined the expressions of vascular endothelial growth factor (VEGF)-C and VEGF-D in soft tissue sarcomas metastasized to lymph nodes. In addition, the effects of the two molecules on the barrier function of a lymphatic endothelial cell monolayer against sarcoma cells were analyzed. We examined 7 patients who had soft tissue sarcomas with lymph node metastases and who had undergone neither chemotherapy nor radiotherapy before lymphadenectomy. Immunohistochemistry revealed that 2 of 7 sarcomas that metastasized to lymph nodes expressed VEGF-C both in primary and metastatic lesions. On the other hand, VEGF-D expression was detected in 4 of 7 primary and 7 of 7 metastatic lesions, respectively. Interestingly, 3 cases that showed no VEGF-D expression at primary sites expressed VEGF-D in metastatic lesions. Recombinant VEGF-C at 10−8 and VEGF-D at 10−7 and 10−8 g/ml significantly increased the random motility of lymphatic endothelial cells compared with controls. VEGF-D significantly increased the migration of sarcoma cells through lymphatic endothelial monolayers. The fact that VEGF-D induced the migration of fibrosarcomas through the lymphatic endothelial monolayer is the probable reason for the strong relationship between VEGF-D expression and lymph node metastasis in soft tissue sarcomas. The important propensities of this molecule for the increase of lymph node metastases are not only lymphangiogenesis but also down-regulation of the barrier function of lymphatic endothelial monolayers, which facilitates sarcoma cells entering the lymphatic circulation.

show abstract

Section: Discussionmentioning

confidence: 57%

Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas

Yanagawa

Shinozaki

Watanabe

et al. 2012

Experimental Cell Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…AMF/PGI acts extracellularly as a cytokine that has the ability to induce the random migration of cells in autocrine pathways [26,27,32]. The molecule stimulates directly the ability of tumor cells to produce lung metastatic nodules [47,48]. Clinically AMF/PGI expression examined by IHC [33][34][35] as well as enzymatic activity in serum [49] has been shown to be associated well with metastatic progression in malignant tumors.…”

Section: Discussionmentioning

confidence: 98%

Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression

Sato

Yanagawa

Dobashi³

et al. 2008

Clin Exp Metastasis

Self Cite

View full text Add to dashboard Cite

Response to neoadjuvant chemotherapy is a significant prognostic factor for osteosarcoma (OS). 18-F-fluorodeoxy-D: -glucose (FDG) positron emission tomography (PET) is a noninvasive imaging modality that correlates with histological grading in musculoskeletal sarcomas. To determine the prognostic value of FDG PET in patients receiving chemotherapy, 13 patients were evaluated by FDG-PET, and followed for more than 4 years. FDG PET standardized uptake values before (SUV1) and after (SUV2) chemotherapy were analyzed and correlated with the expression of metastasis-related glycolytic enzyme, autocrine motility factor (AMF)/phosphoglucose isomerase (PGI) by immunohistochemical examination in surgically excised tumors. Although mean SUV1 for OS patients with metastatic lesions were similar to those in the completely disease-free (CDF) group (6.5 vs. 6.6, respectively, P = 0.975), mean SUV2 for OS with metastatic lesions were significantly higher than those in the CDF group (5.1 vs. 2.5, respectively, P = 0.0445). Interestingly, immunohistochemical analysis using anti-AMF/PGI antibody revealed that SUV2 correlated significantly with the AMF/PGI staining titers (P = 0.0303), while no correlation between SUV1 and the AMF/PGI staining titers existed (P = 0.964). The present study suggests that FDG PET after chemotherapy may provide information for AMF/PGI-related metastatic potentiality of residual tumors located out side of the area surgically resected afterward, and then lead to a useful prediction of the patients' prognosis.

show abstract

“…AMF receptor is also engaged in tumour cell motility (Nabi et al, , 1992Watanabe et al, 1991a). These studies mainly focus on the motility of fibrosarcoma (Watanabe et al, 1991a;Watanabe et al, 1994), fibroblast (Silletti and Raz, 1993) and melanoma cells (Liotta et al, 1986;Silletti et al, 1991;Stracke et al, 1992).…”

Section: Discussionmentioning

confidence: 99%

Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer

Hirono

Fushida²,

Yonemura³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary Up-regulation of autocrine motility factor receptor (AMF-R) expression has been shown to be associated with invasion and metastasis of experimental tumour systems and human neoplasms. Monoclonal antibodies against AMF-R (gp78) were used to stain 221 primary gastric cancer specimens, and level of expression was examined in relation to pathological stage and prognostic values. In 125 out of 221 (56.6%) patients, gp78 was detected. Expression of gp78 was associated with macroscopic type, lymphatic and venous invasions, and lymph node and peritoneal metastasis. The level of gp78 expression in the cancer specimens was associated with histopathological stage and grade of tumour penetration. Positive gp78 expression was significantly associated with poor prognosis (P<0.001). This significant relationship remained among patients in stages II and III. The results suggest that gp78 expression could be used as a prognostic marker in gastric cancer patients.Keywords: gastric cancer; autocrine motility factor receptor; cell motility; invasion; metastasis The incidence of gastric carcinoma is the highest of all carcinomas, and it is the leading cause of death from cancer in Japan. In spite of the improvement in surgical treatment and chemotherapy, the prognosis in this disease is still poor owing to local recurrence or metastasis (Baba et al., 1995; Bonenkamp et al., 1995;Hallissey et al., 1994;Nakazato et al., 1994).Many investigators study the mechanism of tumour cell invasion and metastasis to better understand local recurrence and metastasis (Nekarda et al., 1994;Nomura et al., 1995; Sato et al., 1994; Yonemura et al., 1995). Among the various steps of invasion or metastasis of the cancer cell, cell motility is one of the important factors that promotes cancer progression (Fidler, 1990;Hart et al., 1989;Liotta et al., 1986;Nabi et al., 1991). However, the relationship between gastric cancer stages and cell motility-regulated factors has not been reported. Thus, it is of obvious interest to study such parameters in order to obtain an insight into the biological behaviour of gastric cancers.Autocrine motility factor (AMF) is a cytokine that is produced and secreted by cancer cells and that stimulates both random and directed cell migration through binding to its receptor, a 78 kDa cell surface glycoprotein (gp78, AMF receptor) (Liotta et al., 1986;Nabi et al., 1990Nabi et al., , 1991Silletti et al., 1991). Recently, a molecular cloning of AMF receptor (AMF-R) was reported (Watanabe et al., 1991a). Expression of this receptor relates to cell motility-regulating effects and also may play an important role in tumour cell invasion or metastasis (Nabi et al., 1992;Watanabe et al., 1991b). Recent studies have demonstrated that increased expression of gp78 is correlated with a high incidence of recurrence and decreased survival of patients with colorectal cancer, bladder cancer and oesophageal cancer (Nakamori et al., 1994;Otto et al., 1994;Maruyama et al., 1995).Here, we studied the expression of gp78 in specimens from ...

show abstract

Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcoma

Cited by 16 publications

References 51 publications

Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas

Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas

Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression

Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer

Contact Info

Product

Resources

About